Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

Tanespimycin is the First Hsp90 Inhibitor to Enter Registration Trials

HAYWARD, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that it has successfully reached a binding agreement with the U.S. Food and Drug Administration (FDA) on the design of its TIME-1 clinical trial, a pivotal Phase 3 trial of its Hsp90 inhibitor tanespimycin as a treatment for patients with multiple myeloma. Through the FDA's Special Protocol Assessment (SPA) process, Kosan and the FDA have reached agreement on overall protocol design, primary efficacy endpoints and data analysis as well as aspects of expected labeling if the data from the pivotal trial are supportive and tanespimycin is approved by the FDA. This pivotal Phase 3 protocol, as well as the overall development program, have also completed the "Scientific Advice" process with the centralized European Medicines Agency (EMEA).

Kosan's registration program for tanespimycin, called Tanespimycin in Myeloma Evaluation or TIME, has been initiated and includes two clinical trials: TIME-1 and TIME-2. TIME-1 is a pivotal Phase 3 trial to be conducted in a first-relapse patient population. TIME-1 will evaluate the clinical benefit of adding tanespimycin to bortezomib and compare these results to those seen with single-agent bortezomib. The Special Protocol Assessment Kosan has completed applies to the TIME-1 trial. TIME-2, which is designed to be supportive of the TIME-1 trial, is a Phase 2/3 trial in patients with relapsed-refractory disease. The TIME-2 trial also has the potential to support registration in the relapsed-refractory setting. Kosan has initiated the TIME-2 trial, which is enrolling patients, and expects to init
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013 The ... for systemic delivery of therapeutic agents has been receiving ... drug delivery showing significant promise. The crucial formulation considerations ... delivery device play a major role in the efficiency ... in the development of new formulation techniques and devices ...
(Date:5/24/2013)... England and BOSTON , May 24, ... discovery and development company, is pleased to announce that it has ... to augment the Company,s business development capabilities in Japan ... more than 15 years of experience in business development, licensing and ... Sciences, Inc., Roche Pharma ( Japan ), Nippon Roche ...
(Date:5/23/2013)... , May 24, 2013 3SBio Inc. ... "Company"), a leading China -based ... marketing biopharmaceutical products, announced today that, at an ... Company,s shareholders voted in favor of the proposal ... and plan of merger dated February 8, 2013, ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
(Date:5/24/2013)... have today released updated guidelines on Hormone Replacement Therapy ... the benefits and the risks. The new guidelines appear ... published by SAGE. , Over the last 11 ... of youth" to being considered extremely risky and only ... of the Women,s Health Initiative (WHI) trial in 2002, ...
(Date:5/24/2013)... May 24, 2013 Today marks the ... online Itinerary Builder. , The redesigned and enhanced ... unique vacation itineraries on their computer or mobile device ... The interactive tool allows users to fill in their ... through and select their choice of vacation packages, accommodations, ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 DiaperBuys.com is ... Baby Photo Contest. Lindsey Willis of Olathe, Kansas, won ... from DiaperBuys. Second prize was a three-month supply ... North Las Vegas, Nev.; and third prize, a one-month ... The contest was run through the company’s Facebook page. ...
(Date:5/24/2013)... 2013 Wednesday, 15th May 2013 | 10am ... to access webinar playback: http://bit.ly/10Rt0ZH , Ongoing regulatory ... markets. Across the globe and particularly in Europe, a number ... M&A activity . For dealmakers, understanding how the likes of ... Tax’ affects your corner of the market will give you ...
(Date:5/24/2013)... 24, 2013 http://www.resource4thepeople.com/defectivedrugs/Zithromax-lawsuits.html ... latest update involving allegations that the use of ... can allegedly cause potentially fatal irregular heart ... May 17, 2013* that Health Canada has joined ... that Zithromax can cause abnormal changes in the ...
Breaking Medicine News(10 mins):Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2Health News:DiaperBuys.com Announces Photo Contest Winners 2Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 2Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 3Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 2Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 3Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 4
... now choose a gender of their liking and some can ... procedure developed at the All India Institute of Medical Sciences ... already given proper gender identities as males or females and ... the premier research and referral institute said. ,"Treatment ...
... now looking at lactate with a much more positive ... brain in the immediate //hours after a traumatic brain ... are right, it could change how emergency room physicians ... in the first critical hours after injury. ...
... screen all 20,000-plus human genes for biological activity, scientists have ... cancer cells are to certain chemotherapy drugs.// ,In ... edition of the journal Nature, researchers at UT Southwestern Medical ... molecules – the first used by a university research center ...
... in full bloom, the American Academy of Otolaryngology – Head ... can do to cope with the pollen in the air, ... // ,This spring, pollen from blooming trees and plants ... causing itching eyes, sneezing, nasal stuffiness, nasal congestion and drainage, ...
... may result in erectile dysfunction, decreased libido, anemia, sarcopenia, ... ,While a low serum testosterone level is ... hypogonadism on overall physical functioning and fall risk has ... 23 issue of the Archives of Internal Medicine, Orwoll ...
... than one-third of Queensland men have never been screened for ... ,Screening for colorectal cancer currently has stronger scientific ... prostate or skin cancer, but a new study in the ... undergo the colorectal cancer test than the other two. ...
Cached Medicine News:Health News:New Procedure Paves Way for Eunuchs to Choose a Gender and Conceive 2Health News:Study Challenges Conventional Treatment of Traumatic Brain Injury 2Health News:Gene Screening Points Way to More Effective Chemotherapy 2Health News:April Showers Bring May Flowers – And Plenty of Pollen, To 2Health News:Low Serum Testosterone Levels Associated With Fall Risk in Elderly Men 2
... Rochester Medical's line of ... intermittent catheters you would ... four product configurations - ... antibacterial hydro - are ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
... Rochester Medical's line ... the intermittent catheters you ... All four product configurations ... and antibacterial hydro - ...
Medicine Products: